辅助奥希替尼：新的治疗标准。
Adjuvant Osimertinib: A New Standard of Care.
机构信息
Division of Hematology, Department of Medicine, Oncology and Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Oncologist. 2021 Apr;26(4):263-265. doi: 10.1002/onco.13634. Epub 2020 Dec 24.
Abstract
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), is the new first line standard of care in metastatic non‐small cell lung cancer (NSCLC) based on improvements in overall survival (OS), control of central nervous system (CNS) disease, and a superior toxicity profile. This commentary highlights interim results from the ADAURA trial, continuing the effort to establish a role for EGFR TKIs in the adjuvant setting.
摘要
奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂（TKI），基于其在总生存期（OS）、中枢神经系统（CNS）疾病控制和更优毒性特征方面的改善，它是转移性非小细胞肺癌（NSCLC）新的一线标准治疗药物。这篇评论重点介绍了 ADAURA 试验的中期结果，该试验继续致力于确定 EGFR TKI 在辅助治疗中的作用。
相似文献
1
Adjuvant Osimertinib: A New Standard of Care.
Oncologist. 2021 Apr;26(4):263-265. doi: 10.1002/onco.13634. Epub 2020 Dec 24.
2
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.
3
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
J Thorac Oncol. 2021 Mar;16(3):368-370. doi: 10.1016/j.jtho.2020.11.027.
4
Osimertinib Called "Home Run" for -Mutant NSCLC.
Cancer Discov. 2020 Jul;10(7):896. doi: 10.1158/2159-8290.CD-NB2020-053. Epub 2020 Jun 2.
5
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.
6
Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.
J Thorac Oncol. 2020 Apr;15(4):e54-e55. doi: 10.1016/j.jtho.2019.11.029.
7
Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
Int J Cancer. 2019 Nov 15;145(10):2884-2885. doi: 10.1002/ijc.32617. Epub 2019 Aug 23.
8
Osimertinib for an older de novo T790M patient with chronic kidney disease.
Geriatr Gerontol Int. 2018 Mar;18(3):503-504. doi: 10.1111/ggi.13230.
9
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
10
Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.
J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.
引用本文的文献
1
Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
Oncologist. 2022 May 6;27(5):407-413. doi: 10.1093/oncolo/oyac021.
2
Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.
Drug Deliv Transl Res. 2022 Oct;12(10):2474-2487. doi: 10.1007/s13346-021-01088-0. Epub 2021 Nov 23.
本文引用的文献
1
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
2
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
3
Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542. doi: 10.1200/EDBK_237863. Epub 2019 May 17.
4
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
5
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
6
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
7
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
8
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.
9
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.
10
Trastuzumab containing regimens for early breast cancer.
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD006243. doi: 10.1002/14651858.CD006243.pub2.
Zotero 插件